Novartis (NYSE: NVS) announced Friday September 4, 2026 that the pelacarsen Phase 3 Lp(a)HORIZON trial did not meet its primary endpoint of reducing major adverse cardiovascular events (a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization) versus placebo in patients with elevated lipoprotein(a) plus established cardiovascular disease on guideline-directed background therapy including lipid-lowering and antihypertensive medications. Pelacarsen (an antisense oligonucleotide targeting hepatic APO(a) production, licensed from Ionis Pharmaceuticals in 2019) did achieve substantial lower Lp(a) levels versus placebo. The trial enrolled roughly 8,000 patients globally over 6 years and represents the largest and most consequential test to date of the Lp(a)-as-causal-cardiovascular-risk-factor hypothesis. The miss substantially raises the bar for Amgen's olpasiran (RNAi, Phase 3 OCEAN(a) ongoing), Silence Therapeutics's zerlasiran (RNAi), and Lilly's lepodisiran (RNAi) — all of which are testing similar Lp(a)-lowering-plus-cardiovascular-outcome frameworks. Ionis and Royalty Pharma both hold economic interests in pelacarsen.
AstraZeneca (NASDAQ: AZN) announced Friday September 4, 2026 that the FDA granted accelerated approval to Etcamah (camizestrant, an oral selective estrogen receptor degrader) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone-receptor-positive HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy. FDA also approved the Guardant360 CDx blood-based next-generation sequencing assay as a companion diagnostic to identify ESR1-mutant patients. Approval was based on the Phase 3 SERENA-6 trial that documented a 56% reduction in disease progression or death versus continued standard-of-care aromatase inhibitor plus CDK4/6 inhibitor treatment in the ESR1-mutated subgroup. SERENA-6 was presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine. Etcamah becomes the first oral SERD approved for the switch-at-emergence-of-ESR1 setting, replacing the fulvestrant intramuscular injection historically used post-progression. AstraZeneca is positioning Etcamah alongside Trodelvy plus Datroway as anchors of the expanded breast-cancer franchise.
Alteogen (KOSDAQ: 196170) announced Wednesday September 2, 2026 an option and license agreement with Novartis (NYSE: NVS) for the development and commercialization of subcutaneous formulations of multiple Novartis products using Alteogen's ALT-B4 (berahyaluronidase alfa) enabled by the proprietary Hybrozyme technology. Terms: up to $3.22 billion in aggregate potential value including option exercise fees, development and commercial milestone payments, plus royalties on net sales. ALT-B4 temporarily depolymerizes hyaluronan in the extracellular matrix, enabling co-administered biologics to disperse and absorb subcutaneously rather than requiring intravenous infusion. The transaction is Alteogen's fourth Hybrozyme deal in 2026 following prior agreements with Merck KGaA, Sanofi, and one undisclosed global pharma. The technology approach mirrors Halozyme Therapeutics's ENHANZE platform (used in Roche's SC Herceptin, Rituxan, and Ocrevus, plus Bristol Myers Squibb's SC Opdivo and Johnson & Johnson's SC Darzalex), and the SC-conversion category has become an anchor commercial strategy for pharma companies looking to extend patent life and improve patient convenience on established IV biologics.
Superluminal Medicines announced Thursday September 3, 2026 an oversubscribed $60 million Series B financing round led by BVF Partners with participation from Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Proceeds will advance the company's lead clinical program (a selective, biased MC4R agonist) into Phase 1 for rare genetic forms of obesity including Bardet-Biedl syndrome (BBS) and hypothalamic obesity, targeting Phase 1 initiation by end of 2026. Superluminal's technology platform uses AI plus GPCR-structural chemistry to design biased agonists with reduced off-target signaling. The MC4R agonist positioning is directly against Rhythm Pharmaceuticals's Imcivree (setmelanotide, the currently-approved MC4R agonist peptide for BBS and hypothalamic obesity) — a small-molecule alternative would have oral bioavailability advantages plus different tolerability profile. Eli Lilly's investor participation extends Lilly's obesity-adjacent equity portfolio.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Saturday September 5, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. Clean tolerability plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
Ionis Pharmaceuticals (NASDAQ: IONS) announced Thursday September 3, 2026 FDA approval of Zanvastro (zilganersen, an intrathecally-administered antisense oligonucleotide designed to reduce glial fibrillary acidic protein / GFAP production) for the treatment of Alexander disease in pediatric and adult patients. The approval is the first-ever disease-modifying therapy for Alexander disease, an ultra-rare autosomal dominant neurodegenerative disorder caused by GFAP gene mutations that presents in infancy through adulthood with progressive motor and cognitive decline. Approval landed 19 days ahead of the September 22, 2026 PDUFA target action date. In the registrational trial, walking speed stayed stable in Zanvastro-treated patients while control patients saw a 33% decline. FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV) alongside the approval; PRVs have historically sold for $150-350 million on secondary markets. Zanvastro follows Ionis's Wainua (eplontersen) commercial franchise for hereditary transthyretin amyloid polyneuropathy and lands after the August 28 CARDIO-TTRansform ATTR-CM Phase 3 primary endpoint miss for the same molecule.
AbbVie (NYSE: ABBV) announced Thursday September 3, 2026 positive topline results from the Phase 3 CERVINO trial of etentamig (an investigational monthly-dosed BCMA x CD3 bispecific T-cell engager) versus investigator's choice of standard available therapies in patients with triple-class-exposed relapsed/refractory multiple myeloma. The 393-patient trial met both dual primary endpoints: 74% objective response rate versus standard therapies plus a 60% reduction in the risk of disease progression or death (hazard ratio 0.40). Median follow-up was 11.4 months; safety was manageable with cytokine release syndrome and infection rates consistent with the BCMA bispecific class. Full CERVINO data will be presented in a plenary session at the 23rd International Myeloma Society Annual Meeting September 23-26, 2026 in Glasgow, Scotland. Etentamig would enter a competitive BCMA bispecific field led by Johnson & Johnson's Tecvayli (teclistamab) and Elrexfio (elranatamab, Pfizer), with the monthly dosing profile positioned as convenience-differentiated versus the weekly and biweekly regimens of the incumbents.
Akeso (HKEX: 9926) and Summit Therapeutics (NASDAQ: SMMT) announced Thursday September 3, 2026 that the pre-specified interim overall survival analysis in the Phase 3 HARMONi-2 trial of ivonescimab (a first-in-class PD-1/VEGF bispecific antibody) met the key secondary endpoint of OS versus Merck's Keytruda (pembrolizumab) in first-line PD-L1-positive metastatic non-small cell lung cancer in China. Ivonescimab demonstrated statistically significant and clinically substantive improvement over pembrolizumab; specific hazard ratio and median OS numbers will be released at an upcoming medical meeting. The primary progression-free survival analysis reported earlier had shown ivonescimab reduced the risk of disease progression or death by 49% with median PFS of 11.14 months versus 5.82 months on pembrolizumab. HARMONi-2 is the fourth Phase 3 trial for ivonescimab to meet its OS endpoint (following biliary tract cancer and two other tumor types). The readout is the first head-to-head Phase 3 OS win for any drug versus Keytruda in first-line NSCLC and reshapes the competitive framing for the emerging PD-1/VEGF bispecific class.
Medicus Pharma (NASDAQ: MDCX) announced Wednesday September 2, 2026 a Co-Development and License Agreement with Pfizer (NYSE: PFE) granting Medicus an exclusive, sublicensable, royalty-bearing worldwide license to develop, manufacture, and commercialize PF-08046031 (CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin / CD228). Terms: $12 million upfront cash to Pfizer, an additional $15 million payable on the first anniversary of the effective date, plus up to $1 billion+ in aggregate milestone payments and low-double-digit tiered royalties on future net sales. Pfizer paid Medicus $2 million in development funding restricted to the CD228V program. Medicus retains sole authority and control of development, manufacture, regulatory approval, and commercialization; Pfizer holds review-and-comment rights on development plans and an option to fund development from the first registrational trial. PF-08046031 originated in the Seagen pipeline acquired by Pfizer in December 2023 and represents one of several Seagen-descended assets Pfizer has out-licensed since the acquisition.
Chiesi Group announced Thursday September 3, 2026 that the European Medicines Agency validated regulatory submissions for the Single Inhaler Triple Therapy (Trimbow, beclomethasone dipropionate / formoterol fumarate / glycopyrronium bromide) and the ICS/LABA combination (Fostair, beclomethasone dipropionate / formoterol fumarate) reformulated with HFA-152a — a next-generation non-PFAS propellant with low global warming potential. The reformulated pressurized metered-dose inhalers are designed to reduce the carbon footprint of the products by up to 90% versus the current HFA-134a formulations. In July 2026, the UK Medicines and Healthcare products Regulatory Agency approved Chiesi's beclomethasone pMDI with HFA-152a as the first UK approval of the next-generation propellant. The Chiesi Carbon Minimal Inhaler program is the pharmaceutical industry's leading environmental sustainability initiative and provides a template for GSK, AstraZeneca, and Teva reformulation of Ellipta/Advair/Symbicort/ProAir portfolios that account for approximately 3% of the UK NHS carbon footprint.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Friday September 4, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026 per company Q2 2026 corporate update. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the GLP-1 class.
uniQure N.V. (NASDAQ: QURE) announced Wednesday September 2, 2026 the submission of a Biologics License Application (BLA) to the U.S. FDA for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational AAV-delivered gene therapy for the treatment of Huntington's disease. The BLA is the first ever submitted for a Huntington's disease therapy of any kind. AMT-130 is delivered by stereotactic intraparenchymal injection into the striatum and expresses a microRNA designed to silence the mutant huntingtin (mHTT) gene. The submission is supported by three-year data from the Phase 1/2 program compared to a propensity score-matched external control from the Enroll-HD natural history database. uniQure also submitted a Marketing Authorisation Application (MAA) to the UK MHRA on the same day. A four-year data readout from the ongoing Phase 1/2 study is expected before end of Q3 2026. AMT-130 previously received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Approval would establish the first disease-modifying therapy for Huntington's, where standard-of-care remains symptom management with tetrabenazine and deutetrabenazine plus antipsychotics.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced Wednesday September 2, 2026 that the Phase 3 Aspire study of apazunersen (GTX-102, an intrathecally-administered antisense oligonucleotide designed to reduce production of the paternal UBE3A antisense transcript in Angelman syndrome) did not meet its primary endpoint of change from Baseline in Bayley-4 cognitive raw score, nor its key secondary endpoint of Multidomain Responder Index (MDRI) net response. The 129-patient trial enrolled ages 4 to 17 with genetically confirmed full maternal UBE3A gene deletion. Safety was consistent with the Phase 1/2 program. The result is the first Phase 3 miss for an antisense drug in Angelman syndrome and closes off the primary regulatory path for GTX-102 in the enrolled population. Ultragenyx will discuss next steps with regulators and continues the Aurora study evaluating GTX-102 in additional Angelman syndrome genotypes and age groups. RARE shares fell substantially in premarket trading. The failure joins Roche/Ionis's tominersen Huntington's disease miss (GENERATION HD1, 2022) and Sage-Biogen's zuranolone MDD approval-with-restrictions as instances where CNS antisense programs failed to translate promising Phase 1/2 signals into Phase 3 wins.
Typewriter Therapeutics announced Thursday September 3, 2026 its emergence from stealth with $56 million in Series A financing co-led by RA Capital Management and AN Venture Partners, with participation from ANRI, Gemseki, and SBI US Gateway Fund. The proceeds will advance the company's target-primed reverse transcription (TPRT) non-viral gene therapy platform toward clinical development, with initial focus on two high-value indications: in-vivo CAR-T and genetic liver diseases. TPRT uses jumping-gene-inspired biology to insert therapeutic DNA at specific target sites without the packaging-size constraints of AAV vectors or the payload delivery constraints of lipid nanoparticles. Typewriter plans to initiate non-human primate studies in late 2026 and establish its first in-vivo CAR-T development candidate over the next 12 months. The financing continues the H2 2026 in-vivo CAR-T financing wave that also delivered Umoja Biopharma's $100 million+ round and Capstan Therapeutics' Series C earlier in the summer.
Invivyd (NASDAQ: IVVD, Waltham, Massachusetts biopharma focused on serious viral infectious diseases) announced Tuesday September 1, 2026 that the Board of Directors appointed Chairman Marc W. Elia as Chief Executive Officer effective August 30, 2026. Elia has led Invivyd's corporate and scientific strategy since joining the board in 2022 and will serve as Chairman and CEO going forward at an annual base salary of $750,000. The board also named Ajay Royan Lead Independent Director and added Ian Sheffield as an independent director. The leadership transition is timed to Phase 3 readouts for VYD2311, an investigational anti-SARS-CoV-2 monoclonal antibody, in the DECLARATION and LIBERTY studies — both expected in the coming weeks. Invivyd's Pemgarda (pemivibart, the previous-generation SARS-CoV-2 antibody for pre-exposure prophylaxis in immunocompromised adults) received Emergency Use Authorization in March 2024 and remains the company's primary commercial product. A DECLARATION/LIBERTY win would extend the pre-exposure prophylaxis franchise and provide the commercial anchor for a broader antibody-plus-vaccine COVID pipeline.
Corbus Pharmaceuticals (NASDAQ: CRBP) continued through Thursday September 3, 2026 the countdown to CANYON-1 Phase 1b topline data for CRB-913 (a once-daily orally-administered peripherally-restricted CB1 inverse agonist for obesity). Last patient last visit was announced August 4, 2026, and topline is expected in September 2026. The 16-week double-blind placebo-controlled dose-ranging study enrolled 240 obese non-diabetic U.S. adults at once-daily doses of 20 mg, 40 mg, and 60 mg with 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The readout is one of the most-watched non-incretin obesity data points on the September calendar. A clean tolerability profile plus dose-responsive weight loss would enable Phase 2 initiation and set up CRB-913 as a differentiated add-on or alternative to the incretin class.
Enveda Biosciences (Boulder, Colorado; AI-enabled natural product discovery platform) continues to draw attention through September 2026 for ENV-308, the first-in-class oral small-molecule mimetic of Lac-Phe (N-lactoyl-phenylalanine, an exercise-produced signaling molecule) whose Phase 1 safety and tolerability data was reported August 18, 2026. The Phase 1 trial in 88 healthy volunteers showed ENV-308 was well-tolerated with low GI side effects and reduced circulating leptin as a biomarker signal that the drug reaches metabolically-active concentrations in humans. In preclinical animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that roughly 1 in 8 U.S. adults have used a GLP-1 medication and most stop within a year for cost, side-effect, or plateau reasons. Phase 2 will test whether ENV-308 helps people maintain weight after stopping GLP-1s. Timeline: realistic earliest approval 2028-2029. ENV-308 joins bimagrumab (Eli Lilly, anti-activin receptor Phase 3), HM17321 (Hanmi-Genentech UCN2 analog, Phase 1), and ARO-INHBE (Arrowhead RNAi, Phase 1/2a) in the muscle-preservation pipeline.
Teva Pharmaceutical Industries (NYSE: TEVA) announced Wednesday September 2, 2026 positive topline results from the ongoing Phase 2a study of TEV-408 (an investigational anti-interleukin-15 monoclonal antibody) in adults with celiac disease already following a gluten-free diet. The 50-patient study met its primary endpoint by demonstrating statistically significant and clinically substantive prevention of gluten-induced intestinal damage versus placebo at Week 8. Key efficacy: LS mean change from baseline in intraepithelial lymphocyte (IEL) density was +27.60 for placebo versus +0.37 for TEV-408 (treatment difference -27.23, 95% CI: -39.67 to -14.79). TEV-408 also demonstrated lower gastrointestinal symptom scores versus placebo on the patient-reported Celiac Disease Symptom Diary. Safety was clean with no signals observed. TEV-408 received FDA Fast Track designation in May 2025 and represents a novel mechanism in celiac disease where no disease-modifying therapies are approved and standard-of-care remains strict gluten-free diet adherence. Teva positioned the win as further validation of its 'pipeline-in-a-product' anti-IL-15 platform strategy.